CMC Biologics and OncoSynergy Form Pact - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CMC Biologics and OncoSynergy Form Pact



CMC Biologics and OncoSynergy have entered into an agreement for cell-line development, process development, analytical development, and manufacturing of non-GMP material to enable early toxicology testing and cGMP material for investigational new drug enabling toxicology studies and Phase I clinical trials. This work will advance OncoSynergy’s OS2966 monoclonal antibody program based on its “targeted synergy” approach–a strategy allowing broad inhibition of multiple fundamental cancer-growth mechanisms with a single drug.  The project will be executed by CMC Biologics at its Copenhagen development and manufacturing facility. OncoSynergy EU SAS in France will lead the project.

Source: CMC Biologics

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here